TABLE 4.
Percentage of Candida species intermediate or resistant to amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, and caspofungin tested at the MRL in 2005 (or 2005 to 2006 for C. nivariensis)a
| Organism | Amphotericin B
|
Flucytosine
|
Fluconazole
|
Itraconazole
|
Voriconazole
|
Caspofungin
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % R | n | % I | % R | n | % I | % R | n | % I | % R | n | % I | % R | n | % I | % R | |
| C. albicans | 1,425 | 0 | 127 | 0 | 2 | 1,816 | 1 | 1 | 1,727 | 1 | 1 | 1,375 | 0 | 0 | 908 | 0 | 0 |
| C. krusei | 74 | 0 | 15 | 47 | 0 | 82 | 77 | 23 | 74 | 82 | 10 | 74 | 3 | 3 | 52 | 0 | 0 |
| C. glabrata | 726 | 0 | 116 | 0 | 2 | 883 | 32 | 12 | 751 | 41 | 56 | 751 | 5 | 7 | 500 | 0 | 0 |
| C. nivariensis | 13 | 0 | 13 | 0 | 0 | 13 | 8 | 54 | 13 | 31 | 62 | 12 | 50 | 0 | 13 | 0 | 0 |
a
Data are adapted from MRL unpublished records and reference 4. Values in boldface indicate organism-antifungal agent combinations in which significant resistance is apparent. Abbreviations: n, number of isolates tested; R, resistant; I, intermediate.